These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34391331)

  • 1. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
    Beshay A; Petersen M; Rhoads JLW
    Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Dermatologic Complications of Lung Cancer Therapies.
    Pugliese SB; Neal JW; Kwong BY
    Curr Treat Options Oncol; 2015 Oct; 16(10):50. PubMed ID: 26338208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
    Bierbrier R; Lam M; Pehr K
    Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 6. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
    Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
    J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
    Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
    Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
    [No Abstract]   [Full Text] [Related]  

  • 8. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
    Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
    Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
    Hsiao YW; Lin YC; Hui RC; Yang CH
    J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
    Gorji M; Joseph J; Pavlakis N; Smith SD
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidermal growth factor receptor inhibitors side effects].
    Guhl G; González-de Arriba A; Daudén E
    Actas Dermosifiliogr; 2006 Jun; 97(5):296-310. PubMed ID: 16956561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors.
    Bierbrier R; Esfahani K; Pehr K
    J Cutan Med Surg; 2022; 26(6):624-625. PubMed ID: 35980317
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.
    Recuero JK; Fitz JR; Pereira AA; Bonamigo RR
    An Bras Dermatol; 2023; 98(4):429-439. PubMed ID: 36990917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
    Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
    J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reader Comment Regarding "Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors".
    Fournier C; Sauder MB
    J Cutan Med Surg; 2023; 27(3):294. PubMed ID: 36927192
    [No Abstract]   [Full Text] [Related]  

  • 19. Differences in Management Between Dermatologists and Oncologists for Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
    Oliel S; Bierbrier R; D'Aguanno K; Esfahani K; Pehr K
    J Cutan Med Surg; 2024; 28(1):79-81. PubMed ID: 38156654
    [No Abstract]   [Full Text] [Related]  

  • 20. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
    Yuan C; Wang B
    J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.